Relora Plus
Relora Plus, licence 80051430: active licence in Health Canada data. The French and European references below do not constitute authorisation for sale in France or an assessment of safety or efficacy.
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
Natural health product licensed in Canada
- Other names
- ThorneFX Relora Complex
- Licence holder
- Thorne Research, Inc.
- NPN or DIN-HM
- 80051430
- Status
- Active licence
- Licence date
- 4 June 2014
- Revision date
- Not provided
- Form
- Capsule
- Route of administration
- Orale
- Application type
- Non traditionnelle
If this product were sold in France
- Conditions légales
Magnolia officinalis Rehder & E.H.Wilson: L'étiquetage doit comporter un avertissement déconseillant l'emploi aux femmes enceintes.
arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
- Conditions légales
Phellodendron amurense Rupr.: L'étiquetage doit comporter un avertissement déconseillant l'emploi aux femmes enceintes.
arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Folate Source : (6s)-5-Methyltetrahydrofolic acid, glucosamine salt | 100.0 mcg | Not calculated |
| 3-Pyridinecarboxamide Source : Niacinamide | 5.0 mg | Not calculated |
| Magnolia officinalis Source : Extrait d'écorce Potency : 8.5 % Honokiol | 68.75 mg | Not calculated |
| Magnolia officinalis Source : Extrait d'écorce | Not specified | Not calculated |
| Phellodendron amurense Source : Extrait d'écorce Potency : 2.5 % Berberine | 22.5 mg | Not calculated |
| Vitamine B12 Source : Méthylcobalamine | 50.0 mcg | 100 µg |
Non-medicinal ingredients
Hypromellose, Amidon prégélatinisé, Silice, Amidon de maïs
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | Not specified | minimum: 2.0 Capsule ; maximum: 2.0 Capsule | minimum: 1.0 Jour(s) ; maximum: 1.0 Jour(s) |
Uses authorised in Canada
Text supplied in English because no French text is available.
Temporarily reduces symptoms of perceived stress. Helps to reduce cortisol, a biomarker of stress.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
No French warning text available in the imported data.
Warnings are available in English on the official record.
Source
Official Health Canada record, licence 80051430
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.